NCT02782312View on ClinicalTrials.gov

Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2013

Conditions
Bronchiectasis
Interventions
DRUG

ICS+LABA

Seretide is inhaled for one year

OTHER

routine therapy

routine therapy for one year

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT02782312 - Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis | Biotech Hunter | Biotech Hunter